MX2009002308A - Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina. - Google Patents

Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina.

Info

Publication number
MX2009002308A
MX2009002308A MX2009002308A MX2009002308A MX2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A MX 2009002308 A MX2009002308 A MX 2009002308A
Authority
MX
Mexico
Prior art keywords
administration
tumor cells
radiation therapy
sensitization
endothelin agonists
Prior art date
Application number
MX2009002308A
Other languages
English (en)
Inventor
Luigi Lenaz
Guru Reddy
Anil Gulati
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of MX2009002308A publication Critical patent/MX2009002308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Abstract

Métodos para sensibilizar células tumorales a la terapia con radiación mediante la administración de un agonista de endotelina tal como el agonista ETB IRL1620.
MX2009002308A 2006-08-31 2007-08-27 Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina. MX2009002308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82419706P 2006-08-31 2006-08-31
PCT/US2007/076903 WO2008027839A1 (en) 2006-08-31 2007-08-27 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Publications (1)

Publication Number Publication Date
MX2009002308A true MX2009002308A (es) 2009-09-07

Family

ID=38920900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002308A MX2009002308A (es) 2006-08-31 2007-08-27 Sensibilizacion de celulas tumorales a una terapia con radiacion mediante la administracion de agonistas de endotelina.

Country Status (15)

Country Link
US (2) US8394757B2 (es)
EP (1) EP2059254B1 (es)
JP (1) JP5306208B2 (es)
KR (1) KR101547361B1 (es)
CN (1) CN101534852B (es)
BR (1) BRPI0722292A2 (es)
CA (1) CA2661833C (es)
DK (1) DK2059254T3 (es)
ES (1) ES2541657T3 (es)
IL (1) IL197335A (es)
MX (1) MX2009002308A (es)
NO (1) NO20091203L (es)
RU (1) RU2009111605A (es)
WO (1) WO2008027839A1 (es)
ZA (1) ZA200901425B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
KR20100057060A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
TWI699403B (zh) 2015-09-25 2020-07-21 日商日本化藥股份有限公司 偶氮化合物、印墨組成物、記錄方法及著色體

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU686018B2 (en) 1994-09-20 1998-01-29 Amcor Packaging (New Zealand) Limited A container
ATE532530T1 (de) 1994-12-12 2011-11-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und/oder spasmen an einer gefässstruktur
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
GB9910155D0 (en) 1999-04-30 1999-06-30 Microbiological Research Agenc Augmented agglutination assay
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
CA2409927A1 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
EP1556073B1 (en) 2002-10-24 2016-01-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US8980222B2 (en) * 2004-11-22 2015-03-17 The Board Of Trustees Of The University Of Illinois Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging
JP2008531589A (ja) 2005-02-22 2008-08-14 スペクトラム・ファーマシューティカルス・インコーポレーテッド 固形腫瘍の治療に貢献するための方法、組成物及び製品
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Also Published As

Publication number Publication date
JP5306208B2 (ja) 2013-10-02
WO2008027839A1 (en) 2008-03-06
ZA200901425B (en) 2010-04-28
CN101534852B (zh) 2013-02-13
JP2010502638A (ja) 2010-01-28
KR101547361B1 (ko) 2015-08-25
CA2661833A1 (en) 2008-03-06
US20130150649A1 (en) 2013-06-13
US8957014B2 (en) 2015-02-17
EP2059254B1 (en) 2015-04-08
US20080318846A1 (en) 2008-12-25
US8394757B2 (en) 2013-03-12
DK2059254T3 (en) 2015-07-13
KR20090069279A (ko) 2009-06-30
ES2541657T3 (es) 2015-07-23
NO20091203L (no) 2009-03-23
IL197335A0 (en) 2011-08-01
EP2059254A1 (en) 2009-05-20
BRPI0722292A2 (pt) 2014-04-15
RU2009111605A (ru) 2010-10-10
CN101534852A (zh) 2009-09-16
IL197335A (en) 2013-07-31
CA2661833C (en) 2016-01-26

Similar Documents

Publication Publication Date Title
IL197335A (en) Sensitization of cancer cells to treatment @ radioactive @ B @ Y @ agonists @ of endothelin
MX2009004748A (es) Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
CA3035532C (en) Psma-targeting compounds and uses thereof
BR112013008480A2 (pt) anticorpos contra tumor e usos específicos dos mesmos
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
GB2531952A (en) SC-ß cells and compositions and methods for generating the same
CL2015003285A1 (es) Arilquinazolinas
CL2012001180A1 (es) Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
NZ726666A (en) Compositions and methods of use of phorbol esters
JO2833B1 (en) Amino pyrazole compound
EP2519542A4 (en) ANTI-CDH3 ANTIBODY AND ITS USE
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
MX2010003415A (es) Proceso ex vivo, rápido y eficiente para la obtención de células presentadoras de antígenos activadas, útiles para las terapias contra el cáncer y enfermedades relacionadas con el sistema inmunológico.
WO2012064967A3 (en) Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
AU2018337947A1 (en) Compositions and methods for predicting response to NaPi2b-targeted therapy
WO2014087240A3 (en) Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis
WO2012016050A3 (en) Chemoradiotherapy for kras-mutant colorectal cancer
MX2010001263A (es) Inyeccion, solucion de inyeccion y preparacion de equipo de inyeccion.

Legal Events

Date Code Title Description
FG Grant or registration